Treatment of M. Meniere with Betahistine: Critical Remarks on the BEMED Study

Ernst A, Schlattmann P, Waldfahrer F, Westhofen M (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Laryngo-Rhino-Otologie Georg Thieme Verlag

Book Volume: 96

Pages Range: 519-521

Journal Issue: 8

DOI: 10.1055/s-0043-113690

Abstract

The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the "number of vertigo attacks lasting longer than 20 min as documented in a patient's diary". The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper.

Involved external institutions

Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen DE Germany (DE) Friedrich-Schiller-Universität Jena DE Germany (DE) Unfallkrankenhaus Berlin DE Germany (DE)

How to cite

APA:

Ernst, A., Schlattmann, P., Waldfahrer, F., & Westhofen, M. (2017). Treatment of M. Meniere with Betahistine: Critical Remarks on the BEMED Study. Laryngo-Rhino-Otologie, 96(8), 519-521. https://dx.doi.org/10.1055/s-0043-113690

MLA:

Ernst, A., et al. "Treatment of M. Meniere with Betahistine: Critical Remarks on the BEMED Study." Laryngo-Rhino-Otologie 96.8 (2017): 519-521.

BibTeX: Download